Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c
August 5, 2025 11:11 AM EDT
Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "OCUL is trading down (-6%, XBI +/- 0%) after reporting 2Q25 earnings. Revenue was roughly in line ($13.5M vs $13.6M) and expenses outpaced expectations ($51.1M vs $43.1M). But we believe the weakness today is caused by the disclosure that the company tapped into its ATM for $97M in... More
August 5, 2025 11:07 AM EDT
Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "Tuesday, before market open, Ocular Therapeutix reported 2Q25 financial results. Management hosted a call to discuss recent progress and outlook for the remainder of 2025. The company reported $13.5M in total revenue vs. our estimated $12.0M and diluted EPS of $(0.39) vs. our... More
